Chrysalis BioTherapeutics, a clinical stage biopharmaceutical company based in Galveston, is positioned to revolutionize lives worldwide.

Chrysalis recently received $10.4 million from the federal BioMedical Advanced Research and Development Authority to continue developing TP508, a drug that remedies the effects of radiation exposure. The drug could serve as a countermeasure to people exposed to radiation through medical treatment, nuclear accidents or any other way.

Myer Lee: (409) 683-5247; myer.lee@galvnews.com and on Twitter @thesquarescriv.

Locations

Reporter

Myer joined The Daily News in later 2020 after previously working at our sister newspaper the Del Rio News-Herald.

Recommended for you

(1) comment

Bailey Jones

[thumbup]

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.